Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bepotastine besilate in pediatric perennial allergic rhinitis
NCT01900054Phase 3Completed
- Sponsor
- Mitsubishi Tanabe Pharma
- Start
- Jun 2013
- Primary completion
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of bepotastine in perennial allergic rhinitis (PAR), sponsored by Mitsubishi Tanabe Pharma. Primary endpoints: Adverse Events at 12 weeks and Adverse Drug Reactions at 12 weeks. Started Jun 2013; status: completed.
02
Drugs
bepotastine
03
Conditions
perennial allergic rhinitis (PAR)
Beyond the preview
Go deeper on NCT01900054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01900054.